🧔♂️ A friendly human may check it before it goes live. More news here
India’s Morphle Labs raises $5m series A to expand globally
Morphle Labs, a healthcare automation company based in Bengaluru, has secured US$5 million in series A funding from Inflexor Ventures.
Morphle Labs plans to use the funds to grow its team, increase manufacturing capacity, seek regulatory approvals, and expand internationally, especially in the US and Europe.
The new investment will also support further research and development in medical device automation.
The company develops robotic and imaging systems for cancer diagnostics, including its main products RoboTome, a robotic microtome for slicing biopsy samples, and MorphoLens, a high-throughput slide scanner.
Founded in 2017, the company focuses on automating histopathology processes, an area that remains largely manual in many labs.
Morphle Labs employs about 100 people and has filed more than 80 patents covering robotics, optics, and imaging.
The team is led by CEO Rohit Hiwale, CTO Ashish Manmode, and COO Sunnel Daniel.
🔗 Source: Morphe Labs
🧠 Food for thought
Implications, context, and why it matters.
Digital pathology vendors can target high-volume US labs for partnerships
- Histopathology automation is gaining use, with five RoboTome RTM-30 units processing 500 slides per hour 1. Cloud storage providers, Laboratory Information System (LIS) integrators, and AI tool developers should map US anatomic pathology networks (laboratory groups that analyze tissue specimens).
- Large hospital systems plus reference labs that adopt whole slide imaging (WSI) will need setups for storage, retrieval, and AI analysis. This opens deals for enterprise software or cloud service providers.
- AI vendors with cancer detection or workflow tools can pitch integration before device makers secure exclusive deals, as labs want to improve Return on Investment (ROI) on automation.
Stay updated on the go with our mobile app.
Get latest insights with smoother, more personalized experience through TIA mobile app.